A Multidisciplinary Approach on the Perioperative Antithrombotic Management of Patients With Coronary Stents Undergoing Surgery: Surgery After Stenting 2

JACC: Cardiovascular Interventions

Volumn 11, Issue 5, 2018, Pages 417-434

  Rossini, Roberta ^a   Tarantini, Giuseppe ^b   Musumeci, Giuseppe ^a   Masiero, Giulia ^b   Barbato, Emanuele ^c   Calabrò, Paolo ^d   Capodanno, Davide ^e,f   Leonardi, Sergio ^g   Lettino, Maddalena ^h   Limbruno, Ugo ⁱ   Menozzi, Alberto ^j   Marchese, U O Alfredo ^k   Saia, Francesco ^l   Valgimigli, Marco ^m   Ageno, Walter ⁿ   Falanga, Anna ^o   Corcione, Antonio ^p   Locatelli, Alessandro ^a   Montorsi, Marco ^h   Piazza, Diego ^e   Stella, Andrea ^l   Bozzani, Antonio ^g   Parolari, Alessandro ^q   Carone, Roberto ^r   Angiolillo, Dominick J ^s   more..

^a S CROCE E CARLE HOSPITAL   (Italy)

^b UNIVERSITY OF PADUA MEDICAL SCHOOL   (Italy)

^c UNIVERSITY OF NAPLES FEDERICO II   (Italy)

^d SECOND UNIVERSITY OF NAPLES   (Italy)

^e UNIVERSITY OF CATANIA   (Italy)

^f UNIVERSITY OF CATANIA   (Italy)

^g FONDAZIONE IRCCS POLICLINICO SAN MATTEO   (Italy)

^h HUMANITAS CLINICAL AND RESEARCH CENTER   (Italy)

ⁱ Primary Care Department   (Italy)

^j UNIVERSITY HOSPITAL OF PARMA   (Italy)

^k ANTHEA HOSPITAL   (Italy)

^l UNIVERSITY OF BOLOGNA   (Italy)

^m BERN UNIVERSITY HOSPITAL   (Switzerland)

ⁿ UNIVERSITY OF INSUBRIA   (Italy)

^o PAPA GIOVANNI XXIII HOSPITAL   (Italy)

^p Ospedale dei Colli   (Italy)

^q UNIVERSITY OF MILAN   (Italy)

^r CITTÀ DELLA SALUTE E DELLA SCIENZA HOSPITAL   (Italy)

^s UNIVERSITY OF FLORIDA COLLEGE OF MEDICINE   (United States)

more..

Author keywords

anticoagulant therapy; antiplatelet therapy; atrial fibrillation; bleeding; stent; surgery; thrombosis

Indexed keywords

ANTICOAGULANT AGENT; ANTITHROMBOCYTIC AGENT; FIBRINOLYTIC AGENT;

ANTICOAGULANT THERAPY; ATRIAL FIBRILLATION; CARDIOLOGIST; CARDIOVASCULAR RISK; CLINICAL ASSESSMENT; CORONARY ANGIOGRAPHY; CORONARY STENTING; DRUG WITHDRAWAL; DUAL ANTIPLATELET THERAPY; ELECTIVE SURGERY; EMERGENCY SURGERY; HUMAN; INTERDISCIPLINARY RESEARCH; ISCHEMIA; MEDICAL TECHNOLOGY; OPERATIVE BLOOD LOSS; PERCUTANEOUS CORONARY INTERVENTION; PERIOPERATIVE PERIOD; PRACTICE GUIDELINE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; RISK ASSESSMENT; STANDARDIZATION; STENT THROMBOSIS; SURGERY; SURGICAL PATIENT; THROMBOSIS PREVENTION; TIME TO TREATMENT; TREATMENT WITHDRAWAL; CHEMICALLY INDUCED; CLINICAL DECISION MAKING; CORONARY ARTERY DISEASE; CORONARY ARTERY THROMBOSIS; DEVICES; DIAGNOSTIC IMAGING; DRUG ADMINISTRATION; PATIENT CARE; POSTOPERATIVE HEMORRHAGE; RISK FACTOR; STENT; TIME FACTOR; TREATMENT OUTCOME;

ANTICOAGULANTS; BLOOD LOSS, SURGICAL; CLINICAL DECISION-MAKING; CORONARY ANGIOGRAPHY; CORONARY ARTERY DISEASE; CORONARY THROMBOSIS; DRUG ADMINISTRATION SCHEDULE; FIBRINOLYTIC AGENTS; HUMANS; PATIENT CARE TEAM; PERCUTANEOUS CORONARY INTERVENTION; PERIOPERATIVE CARE; PLATELET AGGREGATION INHIBITORS; POSTOPERATIVE HEMORRHAGE; RISK ASSESSMENT; RISK FACTORS; STENTS; SURGICAL PROCEDURES, OPERATIVE; TIME FACTORS; TREATMENT OUTCOME;

EID: 85042787413     PISSN: 19368798     EISSN: 18767605     Source Type: Journal    
DOI: 10.1016/j.jcin.2017.10.051     Document Type: Review

References (67)

1. Benjamin, E.J., Blaha, M.J., Chiuve, S.E., et al., American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Heart Disease and Stroke Statistics-2017 Update: a report from the American Heart Association. Circulation 135 (2017), e146–e603.
2. Moschovitis, A., Cook, S., Meier, B., Percutaneous coronary interventions in Europe in 2006. EuroIntervention 6 (2010), 189–194.
3. Brilakis, E.S., Banerjee, S., Berger, P.B., Perioperative management of patients with coronary stents. J Am Coll Cardiol 49 (2007), 2145–2150.
4. Capodanno, D., Angiolillo, D.J., Management of antiplatelet therapy in patients with coronary artery disease requiring cardiac and noncardiac surgery. Circulation 128 (2013), 2785–2798.
5. Douketis, J., Berger, P.B., Dunn, A.S., et al. The perioperative management of antithrombotic therapy: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest 133 (2008), 299–339.
6. Douketis, J.D., Spyropoulos, A.C., Spencer, F.A., et al., American College of Chest Physicians. Perioperative management of antithrombotic therapy: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest 141 (2012), e326–e350.
7. Schouten, O., van Domburg, R.T., Bax, J.J., et al. Noncardiac surgery after coronary stenting: early surgery and interruption of antiplatelet therapy are associated with an increase in major adverse cardiac events. J Am Coll Cardiol 49 (2007), 122–124.
8. Albaladejo, P., Marret, E., Samama, C.M., et al. Non-cardiac surgery in patients with coronary stents: the RECO study. Heart 97 (2011), 1566–1572.
9. Rossini, R., Musumeci, G., Capodanno, D., et al. Perioperative management of oral antiplatelet therapy and clinical outcomes in coronary stent patients undergoing surgery. Results of a multicentre registry. Thromb Haemost 113 (2015), 272–282.
10. Valgimigli, M., Bueno, H., Byrne, R.A., et al. 2017 ESC focused update on dual antiplatelet therapy in coronary artery disease developed in collaboration with EACTS: The Task Force for dual antiplatelet therapy in coronary artery disease of the European Society of Cardiology (ESC) and of the European Association for Cardio-Thoracic Surgery (EACTS). Eur Heart J 39 (2018), 213–260.
11. Kristensen, S.D., Knuuti, J., Saraste, A., et al. 2014 ESC/ESA guidelines on non-cardiac surgery: cardiovascular assessment and management: the Joint Task Force on non-cardiac surgery: cardiovascular assessment and management of the European Society of Cardiology (ESC) and the European Society of Anaesthesiology (ESA). Eur Heart J 35 (2014), 2383–2431.
12. Levine, G.N., Bates, E.R., Bittl, J.A., et al. 2016 ACC/AHA guideline focused update on duration of dual antiplatelet therapy in patients with coronary artery disease: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. J Am Coll Cardiol 68 (2016), 1082–1115.
13. Rossini, R., Musumeci, G., Visconti, L.O., et al. Italian Society of Invasive Cardiology (SICI-GISE) Italian Association of Hospital Cardiologists (ANMCO) Italian Society for Cardiac Surgery (SICCH) Italian Society of Vascular and Endovascular Surgery (SICVE) Italian Association of Hospital Surgeons (ACOI) Italian Society of Surgery (SIC) Italian Society of Anaesthesia and Intensive Care Medicine (SIAARTI) Lombard Society of Surgery (SLC) Italian Society of Maxillofacial Surgery (SICMF) Italian Society of Reconstructive Plastic Surgery and Aesthetics (SICPRE) Italian Society of Thoracic Surgeons (SICT) Italian Society of Urology (SIU) Italian Society of Orthopaedics and Traumatology (SIOT) Italian Society of Periodontology (SIdP) Italian Federation of Scientific Societies of Digestive System Diseases Lombardia (FISMAD) Association of Obstetricians Gynaecologists Italian Hospital Lombardia (AOGOI), Society of Ophthalmology Lombardia (SOL). Perioperative management of antiplatelet therapy in patients with coronary stents undergoing cardiac and non-cardiac surgery: A consensus document from Italian cardiological, surgical and anaesthesiological societies. EuroIntervention 10 (2014), 38–46.
14. Rossini, R., Angiolillo, D.J., Musumeci, M., et al. Antiplatelet therapy and outcome in patients undergoing surgery following coronary stenting: results of the Surgery After Stenting Registry. Catheter Cardiovasc Intv 89 (2017), E13–E25.
15. Bittl, J.A., Baber, U., Bradley, S.M., Wijeysundera, D.N., Duration of dual antiplatelet therapy: A systematic review for the 2016 ACC/AHA guideline focused update on duration of dual antiplatelet therapy in patients with coronary artery disease: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. Circulation 134 (2016), e156–e178.
16. Windecker, S., Kolh, P., Alfonso, F., et al., Task Force on Myocardial Revascularization of the European Society of Cardiology (ESC) and the European Association or Cardio-Thoracic Surgery (EACTS) Developed with the special contribution of the European Association of Percutaneous Cardiovascular Interventions (EAPCI). 2014 ESC/EACTS Guidelines on myocardial revascularization. Eur Heart J, 35, 2014 2541–19.
17. Rajagopalan, S., Ford, I., Bachoo, P., et al. Platelet activation, myocardial ischemic events and postoperative non-response to aspirin in patients undergoing major vascular surgery. J Thromb Haemost 5 (2007), 2028–2035.
18. Banerjee, S., Angiolillo, D.J., Boden, W.E., et al. Use of antiplatelet therapy/DAPT for post-PCI patients undergoing noncardiac surgery. J Am Coll Cardiol 69 (2017), 1861–1870.
19. Saia, F., Belotti, L.M., Guastaroba, P., et al. Risk of adverse cardiac and bleeding events following cardiac and noncardiac surgery in patients with coronary stent: how important is the interplay between stent type and time from stenting to surgery?. Circ Cardiovasc Qual Outcomes 9 (2016), 39–47.
20. Stone, G.W., Gao, R., Kimura, T., et al. 1-year outcomes with the Absorb bioresorbable scaffold in patients with coronary artery disease: a patient-level, pooled meta-analysis. Lancet 387 (2016), 1277–1289.
21. Capodanno, D., Angiolillo, D.J., Antiplatelet therapy after implantation of bioresorbable vascular scaffolds: a review of the published data, practical recommendations, and future directions. J Am Coll Cardiol Intv 10 (2017), 425–437.
22. Hawn, M.T., Graham, L.A., Richman, J.R., et al. The incidence and timing of non cardiac surgery after cardiac stent implantation. J Am Coll Surg 214 (2012), 658–666.
23. Egholm, G., Kristensen, S.D., Thim, T., et al. Risk associated with surgery within 12 months after coronary drug-eluting stent implantation. J Am Coll Cardiol 68 (2016), 2622–2632.
24. Mahmoud, K.D., Sanon, S., Habermann, E.B., et al. Perioperative cardiovascular risk of prior coronary stent implantation among patients undergoing noncardiac surgery. J Am Coll Cardiol 67 (2016), 1038–1049.
25. Mehran, R., Baber, U., Steg, P.G., et al. Cessation of dual antiplatelet treatment and cardiac events after percutaneous coronary intervention (PARIS): 2 year results from a prospective observational study. Lancet 382 (2013), 1714–1722.
26. Nuttall, G.A., Brown, M.J., Stombaugh, J.W., et al. Time and cardiac risk of surgery after bare-metal stent percutaneous coronary intervention. Anesthesiology 109 (2008), 588–595.
27. Wilson, S.H., Fasseas, P., Orford, J.L., et al. Clinical outcome of patients undergoing non-cardiac surgery in the 2 months following coronary stenting. J Am Coll Cardiol 42 (2003), 234–240.
28. Kaluza, G.L., Joseph, J., Lee, J.R., et al. Catastrophic outcomes of noncardiac surgery soon after coronary stenting. J Am Coll Cardiol 35 (2000), 1288–1294.
29. Cruden, N.L., Harding, S.A., Flapan, A.D., et al. Previous coronary stent implantation and cardiac events in patients undergoing noncardiac surgery. Circ Cardiovasc Interv 3 (2010), 236–242.
30. Tokushige, A., Shiomi, H., Morimoto, T., et al., CREDO-Kyoto PCI/CABG registry cohort-2 investigators. Incidence and outcome of surgical procedures after coronary bare-metal and drug-eluting stent implantation: a report from the CREDO-Kyoto PCI/CABG registry cohort-2. Circ Cardiovasc Interv 5 (2012), 237–246.
31. Holmes, D.R. Jr., Kereiakes, D.J., Garg, S., et al. Stent thrombosis. J Am Coll Cardiol 56 (2010), 1357–1365.
32. Iakovou, I., Schmidt, T., Bonizzoni, E., et al. Incidence, predictors, and outcome of thrombosis after successful implantation of drug-eluting stents. JAMA 293 (2005), 2126–2130.
33. Airoldi, F., Colombo, A., Morici, N., Latib, A., et al. Incidence and predictors of drug-eluting stent thrombosis during and after discontinuation of thienopyridine treatment. Circulation 116 (2007), 745–754.
34. Giustino, G., Chieffo, A., Palmerini, T., et al. Efficacy and safety of dual antiplatelet therapy after complex PCI. J Am Coll Cardiol 68 (2016), 1851–1864.
35. Bhatt, D.L., Eagle, K.A., Ohman, E.M., et al., REACH Registry Investigators. Comparative determinants of 4-year cardiovascular event rates in stable outpatients at risk of or with atherothrombosis. JAMA 304 (2010), 1350–1357.
36. Holcomb, C.N., Graham, L.A., Richman, J.S., et al. The incremental risk of coronary stents on postoperative adverse events: a matched cohort study. Ann Surg 263 (2016), 924–930.
37. Garg, S., Sarno, G., Garcia-Garcia, H.M., et al., ARTS-II Investigators. A new tool for the risk stratification of patients with complex coronary artery disease: the Clinical SYNTAX Score. Circ Cardiovasc Interv 3 (2010), 317–326.
38. Parasca, C.A., Head, S.J., Milojevic, M., et al., SYNTAX Investigators. Incidence, characteristics, predictors, and outcomes of repeat revascularization after percutaneous coronary intervention and coronary artery bypass grafting: the SYNTAX trial at 5 years. J Am Coll Cardiol Intv 9 (2016), 2493–2507.
39. Généreux, P., Palmerini, T., Caixeta, A., et al. Quantification and impact of untreated coronary artery disease after percutaneous coronary intervention: the residual SYNTAX (Synergy Between PCI with Taxus and Cardiac Surgery) score. J Am Coll Cardiol 59 (2012), 2165–2174.
40. Huber, K.C., Evans, M.A., Bresnahan, J.F., et al. Outcome of non cardiac operations in patients with severe coronary-artery disease successfully treated pre-operatively with coronary angioplasty. Mayo Clin Proc 67 (1992), 15–21.
41. Wijeysundera, D.N., Wijeysundera, H.C., Yun, L., et al. Risk of elective major non cardiac surgery after coronary stent insertion: a population-based study. Circulation 126 (2012), 1355–1362.
42. Hawn, M.T., Graham, L.A., Richman, J.S., Itani, K.M., Henderson, W.G., Maddox, T.M., Risk of major adverse cardiac events following non cardiac surgery in patients with coronary stents. JAMA 310 (2013), 1462–1472.
43. Franchi, F., Rollini, F., Muñiz-Lozano, A., Cho, J.R., Angiolillo, D.J., Cangrelor: a review on pharmacology and clinical trial development. Expert Rev Cardiovasc Ther 11 (2013), 1279–1291.
44. Angiolillo, D.J., Schneider, D.J., Bhatt, D.L., et al. Pharmacodynamic effects of cangrelor and clopidogrel: the platelet function substudy from the cangrelor versus standard therapy to achieve optimal management of platelet inhibition (CHAMPION) trials. J Thromb Thrombolysis 34 (2012), 44–55.
45. Bhatt, D.L., Stone, G.W., Mahaffey, K.W., et al., CHAMPION PHOENIX Investigators. Effect of platelet inhibition with cangrelor during PCI on ischemic events. N Engl J Med 368 (2013), 1303–1313.
46. Angiolillo, D.J., Firstenberg, M.S., Price, M.J., et al. Bridging antiplatelet therapy with cangrelor un patients undergoing cardiac surgery. A randomized control trial. JAMA 307 (2012), 265–274.
47. Angiolillo, D.J., Rollini, F., Storey, R.F., et al. International expert consensus on switching platelet P2Y12 receptor-inhibiting therapies. Circulation 136 (2017), 1955–1975.
48. Savonitto, S., Caracciolo, M., Cattaneo, M., De Servi, S., Management of patients with recently implanted coronary stents on dual antiplatelet therapy who need to undergo major surgery. J Thromb Haemost 9 (2011), 2133–2142.
49. Pickett, A.M., Taylor, D.A., Ackman, M.L., Prolonged infusion of eptifibatide as bridge therapy between bare-metal stent insertion and cardiovascular surgery: case report and review of the literature. Pharmacotherapy 30 (2010), 127–133e.
50. Devereaux, P.J., Mrkobrada, M., Sessler, D.I., et al., POISE-2 Investigators. Aspirin in patients undergoing noncardiac surgery. N Engl J Med 370 (2014), 1494–1503.
51. Graham, M.M., Sessler, D.I., Parlow, J.L., et al. Aspirin in patients with previous percutaneous coronary intervention undergoing noncardiac surgery. Ann Intern Med 168 (2018), 237–244.
52. Hansson, E.C., Jidéus, L., Åberg, B., et al. Coronary artery bypass grafting-related bleeding complications in patients treated with ticagrelor or clopidogrel: a nationwide study. Eur Heart J 37 (2016), 189–197.
53. Gherli, R., Mariscalco, G., Dalén, M., et al. Safety of preoperative use of ticagrelor with or without aspirin compared with aspirin alone in patients with acute coronary syndromes undergoing coronary artery bypass grafting. JAMA Cardiol 1 (2016), 921–928.
54. van Diepen, S., Tricoci, P., Podder, M., et al. Efficacy and safety of vorapaxar in non-ST-segment elevation acute coronary syndrome patients undergoing noncardiac surgery. J Am Heart Assoc, 4, 2015, e002546.
55. European Heart Rhythm Association, European Association for Cardio-Thoracic Surgery, Camm, A.J., et al. Guidelines for the management of atrial fibrillation: the Task Force for the Management of Atrial Fibrillation of the European Society of Cardiology (ESC). Eur Heart J 31 (2010), 2369–2429 Erratum in: Eur Heart J 2011;32:1172.
56. Heidbuchel, H., Verhamme, P., Alings, M., et al. Updated European Heart Rhythm Association Practical Guide on the use of non-vitamin K antagonist anticoagulants in patients with non-valvular atrial fibrillation. Europace 17 (2015), 1467–1507.
57. Schulman, S., Crowther, M.A., How I treat with anticoagulants in 2012: new and old anticoagulants, and when and how to switch. Blood 119 (2012), 3016–3023.
58. Pollack, C.V. Jr., Reilly, P.A., van Ryn, J., et al. Idarucizumab for dabigatran reversal - full cohort analysis. N Engl J Med 377 (2017), 431–441.
59. Lip, G.Y., Windecker, S., Huber, K., et al. Management of antithrombotic therapy in atrial fibrillation patients presenting with acute coronary syndrome or undergoing percutaneous coronary or valve interventions: a joint consensus document of the European Society of Cardiology Working Group on Thrombosis, European Heart Rhythm Association (EHRA), European Association of Percutaneous Cardiovascular Interventions (EAPCI) and European Association of Acute Cardiac Care (ACCA) endorsed by the Heart Rhythm Society (HRS) and Asia-Pacific Heart Rhythm Society (APHRS). Eur Heart J 35 (2014), 3155–3179.
60. Douketis, J.D., Spyropoulos, A.C., Kaatz, S., et al., BRIDGE Investigators. Perioperative bridging anticoagulation in patients with atrial fibrillation. N Engl J Med 373 (2015), 823–833.
61. Spyropoulos, A.C., Bauersachs, R.M., Omran, H., Cohen, M., Periprocedural bridging therapy in patients receiving chronic oral anticoagulation therapy. Curr Med Res Opin 22 (2006), 1109–1122.
62. Sié P., Samama, C.M., Godier, A., et al., French Study Group on Thrombosis and Haemostasis. Surgery and invasive procedures in patients on long-term treatment with direct oral anticoagulants: thrombin or factor-Xa inhibitors. Recommendations of the Working Group on Perioperative Haemostasis and the French Study Group on Thrombosis and Haemostasis. Arch Cardiovasc Dis 104 (2011), 669–676.
63. Bell, B.R., Spyropoulos, A.C., Douketis, J.D., Perioperative management of the direct oral anticoagulants: a case-based review. Hematol Oncol Clin North Am 30 (2016), 1073–1084.
64. Mega, J.L., Braunwald, E., Wiviott, S.D., et al., ATLAS ACS 2–TIMI 51 Investigators. Rivaroxaban in patients with a recent acute coronary syndrome. N Engl J Med 366 (2012), 9–19.
65. Healey, J.S., Eikelboom, J., Douketis, J., et al., RE-LY Investigators. Periprocedural bleeding and thromboembolic events with dabigatran compared with warfarin: results from the Randomized Evaluation of Long-Term Anticoagulation Therapy (RE-LY) randomized trial. Circulation 126 (2012), 343–348.
66. Siegal, D.M., Managing target-specific oral anticoagulant associated bleeding including an update on pharmacological reversal agents. J Thromb Thrombolysis 39 (2015), 395–402.
67. Connoly, S.J., Milling, T.J., Eikelboom, J.W., et al. Andexanet alfa for acute major bleeding associated with factor Xa inhibitors. N Engl Med 375 (2016), 1131–1141.